BioCryst to Report Second Quarter 2021 Financial Results on August 5
July 22 2021 - 7:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that
the company will report its second quarter 2021 financial results
on Thursday, August 5, 2021.
BioCryst management will host a conference call
and webcast at 8:30 a.m. ET that day to discuss the financial
results and provide a corporate update.
The live call may be accessed by dialing
877-303-8027 for domestic callers and 760-536-5165 for
international callers and using conference ID # 9886913. A live
webcast of the call and any slides will be available online at the
investors section of the company website at www.biocryst.com. A
telephone replay of the call will be available by dialing
855-859-2056 for domestic callers or 404-537-3406 for international
callers and entering the conference ID # 9886913.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral,
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. Oral, once-daily
ORLADEYO® (berotralstat) is approved in the United
States, the European Union, Japan and the United Kingdom for the
prevention of HAE attacks in adults and pediatric patients 12 years
and older. BioCryst has several ongoing development programs
including BCX9930, an oral Factor D inhibitor for the treatment of
complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva, and
galidesivir, a potential treatment for Marburg virus disease and
Yellow Fever. RAPIVAB® (peramivir injection), a viral
neuraminidase inhibitor for the treatment of influenza, has
received regulatory approval in the U.S., Canada, Australia, Japan,
Taiwan and Korea. Post-marketing commitments for RAPIVAB are
ongoing. For more information, please visit the company’s website
at www.biocryst.com.
BCRXW
Contact:InvestorsJohn Bluth+1
919 859 7910jbluth@biocryst.com
MediaCatherine Collier Kyroulis+1 917 886
5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024